Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -260.45% is 310% below its 5-year average of -63.55%, near the low end of its 5-year range (-260.45%–-23.05%).
As of the fiscal period ended Tuesday, June 30, 2026. 67.95% below its 12-month average of -155.07%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -260.45%.
RETURN ON EQUITY (ROE)
-260.45%
RETURN ON EQUITY (ROE) AVG TTM
-155.07%
RETURN ON EQUITY (ROE) AVG 3Y
-83.02%
RETURN ON EQUITY (ROE) AVG 5Y
-63.55%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-67.95%
CURRENT VS 3Y AVG
-213.71%
CURRENT VS 5Y AVG
-309.81%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.75%
median of 682 covered companies
CURRENT VS SECTOR MEDIAN
-539.07%
vs the sector median at left
CVRx, Inc.
Market Cap
$44.32M
Return on Equity (ROE)
-260.45%
TTM Avg
-155.07%
3Y Avg
-83.02%
5Y Avg
-63.55%
Market Cap
$44.41M
Return on Equity (ROE)
-288.49%
TTM Avg
-102.07%
3Y Avg
-71.41%
5Y Avg
-78.05%
Market Cap
$43.78M
Return on Equity (ROE)
-161.19%
TTM Avg
-40.99%
3Y Avg
-40.41%
5Y Avg
-33.61%
Market Cap
$43.65M
Return on Equity (ROE)
-102.45%
TTM Avg
30.59%
3Y Avg
217.16%
5Y Avg
155.68%
Market Cap
$45.41M
Return on Equity (ROE)
-212.45%
TTM Avg
-170.64%
3Y Avg
-104.70%
5Y Avg
-78.05%
Market Cap
$43.51M
Return on Equity (ROE)
513.56%
TTM Avg
488.17%
3Y Avg
265.30%
5Y Avg
226.12%
Market Cap
$45.92M
Return on Equity (ROE)
123.04%
TTM Avg
-60.38%
3Y Avg
-75.18%
5Y Avg
-82.51%
Market Cap
$41.92M
Return on Equity (ROE)
-8.23%
TTM Avg
-18.98%
3Y Avg
-38.34%
5Y Avg
-43.89%
Market Cap
$47.83M
Return on Equity (ROE)
-17.84%
TTM Avg
-32.49%
3Y Avg
-23.88%
5Y Avg
-18.14%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CVRx, Inc. (CVRX) | $44.32M | -260.45% | -155.07% | -83.02% | -63.55% |
| Rapid Micro Biosystems, Inc. (RPID)vs › | $44.41M | -288.49% | -102.07% | -71.41% | -78.05% |
| Nano-X Imaging Ltd. (NNOX)vs › | $43.78M | -161.19% | -40.99% | -40.41% | -33.61% |
| BioStem Technologies, Inc. (BSEM)vs › | $43.65M | -102.45% | 30.59% | 217.16% | 155.68% |
| Werewolf Therapeutics, Inc. (HOWL)vs › | $45.41M | -212.45% | -170.64% | -104.70% | -78.05% |
| SANUWAVE Health Inc. (SNWV)vs › | $43.51M | 513.56% | 488.17% | 265.30% | 226.12% |
| DarioHealth Corp. (DRIO)vs › | $45.92M | 123.04% | -60.38% | -75.18% | -82.51% |
| Precipio, Inc. (PRPO)vs › | $41.92M | -8.23% | -18.98% | -38.34% | -43.89% |
| Precision Optics Corporation, Inc. (POCI)vs › | $47.83M | -17.84% | -32.49% | -23.88% | -18.14% |
| Filana Therapeutics, Inc. (FLNA)vs › | $40.22M | -66.47% | -61.13% | -30.57% | -24.45% |
ROE
-260.5%
ROA
-56.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -260.45% |
| 2026-03-31 | -180.91% |
| 2025-12-31 | -135.56% |
| 2025-09-30 | -108.26% |
| 2025-06-30 | -90.19% |
| 2025-03-31 | -74.32% |
| 2024-12-31 | -84.39% |
| 2024-09-30 | -89.71% |
| 2024-06-30 | -98.45% |
| 2024-03-31 | -78.49% |
| 2023-12-31 | -54.25% |
| 2023-09-30 | -51.40% |
| 2023-06-30 | -48.23% |
| 2023-03-31 | -42.96% |
| 2022-12-31 | -37.94% |
| 2022-09-30 | -35.06% |
| 2022-06-30 | -29.70% |
| 2022-03-31 | -32.49% |
| 2021-12-31 | -29.51% |
| 2021-09-30 | -23.05% |
